Experimental immune cell therapy shows promise for tough blood cancers

NCT ID NCT04620681

Completed Disease control Sponsor: H. Lee Moffitt Cancer Center and Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested a new treatment for people with myelodysplastic syndrome (MDS) or secondary acute myeloid leukemia (AML) who had not responded to prior therapy. The treatment involved giving specially prepared donor immune cells (with CD8 cells removed to reduce risk) along with standard chemotherapy. The main goal was to find a safe dose and see if the combination could control the disease. Only 19 people took part, so the results are very preliminary.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CD8-depleted donor immune cells (lymphocytes) plus standard chemotherapy
What this could lead to: If successful, this approach could offer a new treatment option for people with MDS or secondary AML who have not responded to standard therapies.
What could go wrong: This is an early-phase trial with only 19 participants, so results may not apply broadly. There are risks of infusion reactions, graft-versus-host disease, or lack of benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myelodysplastic syndrome Myelodysplastic Syndromes therapy related acute myeloid leukemia and myelodysplastic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELODYSPLASTIC SYNDROMES SECONDARY ACUTE MYELOID LEUKEMIA

Contacts and locations

Locations

Moffitt Cancer Center

Tampa, Florida, 33612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.